Genes involved in muscle contractility and nutrient signaling pathways within celiac disease risk loci show differential mRNA expression by Monten, C. et al.
Chalmers Publication Library
Genes involved in muscle contractility and nutrient signaling pathways within celiac
disease risk loci show differential mRNA expression
This document has been downloaded from Chalmers Publication Library (CPL). It is the author´s
version of a work that was accepted for publication in:
Bmc Medical Genetics (ISSN: 1471-2350)
Citation for the published paper:
Monten, C. ; Gudjonsdottir, A. ; Browaldh, L. et al. (2015) "Genes involved in muscle
contractility and nutrient signaling pathways within celiac disease risk loci show differential
mRNA expression". Bmc Medical Genetics, vol. 16 pp. artikel nr 44.
http://dx.doi.org/10.1186/s12881-015-0190-1
Downloaded from: http://publications.lib.chalmers.se/publication/219764
Notice: Changes introduced as a result of publishing processes such as copy-editing and
formatting may not be reflected in this document. For a definitive version of this work, please refer
to the published source. Please note that access to the published version might require a
subscription.
Chalmers Publication Library (CPL) offers the possibility of retrieving research publications produced at Chalmers
University of Technology. It covers all types of publications: articles, dissertations, licentiate theses, masters theses,
conference papers, reports etc. Since 2006 it is the official tool for Chalmers official publication statistics. To ensure that
Chalmers research results are disseminated as widely as possible, an Open Access Policy has been adopted.
The CPL service is administrated and maintained by Chalmers Library.
(article starts on next page)
Montén et al. BMC Medical Genetics  (2015) 16:44 
DOI 10.1186/s12881-015-0190-1RESEARCH ARTICLE Open AccessGenes involved in muscle contractility and
nutrient signaling pathways within celiac
disease risk loci show differential mRNA
expression
Caroline Montén1*, Audur H. Gudjonsdottir2, Lars Browaldh3, Henrik Arnell4, Staffan Nilsson5, Daniel Agardh1
and Åsa Torinsson Naluai6Abstract
Background: Risk gene variants for celiac disease, identified in genome-wide linkage and association studies, might
influence molecular pathways important for disease development. The aim was to examine expression levels of
potential risk genes close to these variants in the small intestine and peripheral blood and also to test if the
non-coding variants affect nearby gene expression levels in children with celiac disease.
Methods: Intestinal biopsy and peripheral blood RNA was isolated from 167 children with celiac disease, 61 with
potential celiac disease and 174 disease controls. Transcript levels for 88 target genes, selected from celiac disease risk
loci, were analyzed in biopsies of a smaller sample subset by qPCR. Differentially expressed genes (3 from the pilot and
8 previously identified) were further validated in the larger sample collection (n = 402) of both tissues and correlated to
nearby celiac disease risk variants.
Results: All genes were significantly down- or up-regulated in the intestinal mucosa of celiac disease children, NTS
being most down-regulated (Fold change 3.6, p < 0.001). In contrast, PPP1R12B isoform C was up-regulated in the celiac
disease mucosa (Fold change 1.9, p < 0.001). Allele specific expression of GLS (rs6741418, p = 0.009), INSR (rs7254060,
p = 0.003) and NCALD (rs652008, p = 0.005) was also detected in the biopsies. Two genes (APPL2 and NCALD) were
differentially expressed in peripheral blood but no allele specific expression was observed in this tissue.
Conclusion: The differential expression of NTS and PPP1R12B indicate a potential role for smooth muscle contractility
and cell proliferation in celiac disease, whereas other genes like GLS, NCALD and INSR suggests involvement of nutrient
signaling and energy homeostasis in celiac disease pathogenesis. A disturbance in any of these pathways might
contribute to development of childhood celiac disease.
Keywords: Celiac Disease, Gene expression, Small intestinal mucosa, Peripheral blood, Single nucleotide polymorphismsBackground
Human leukocyte antigen (HLA) class II molecules on
chromosome 6 are necessary factors for celiac disease
where 90–95 % of all affected patients carry the HLA-
DQA1*05:01-DQB1*02:01 haplotype and the remainder
carry either the HLA-DQA1*03:01-DQB1*03:02 or HLA-
DQA1*02:01-DQB1*02:02 haplotype [1]. Although the* Correspondence: caroline.monten@med.lu.se
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creativecommons.org/publicdomain/zero/1.0/HLA association with celiac disease is well established,
30 % of the general Caucasian population carry risk
HLA alleles without developing the disease [2]. More-
over, the odds ratios (OR) for monozygotic twins to be
concordant for celiac disease was 17 compared to 1.4 for
DQ identical dizygotic twins independent of the DQ at
risk genotype [3]. This indicates that non-HLA genetic
factors play a role in disease susceptibility. Genome wide
association studies (GWASs) in celiac disease have iden-
tified altogether 58 non-HLA risk variants within 40 dif-
ferent loci [4–7]. Expression quantitative trait locusarticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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liac disease associated risk regions contain single nucleo-
tide polymorphisms (SNPs) that regulate the expression
of nearby genes of which a majority are involved in the
control of immune response [5]. With the aim of unco-
vering additional genetic risk factors for celiac disease,
we recently performed a GWAS in Scandinavian sib-
pairs with celiac disease [7]. Functional clustering ana-
lyses of genes located nearby the strongest associated
SNPs generated possible susceptibility genes involved in
pathways like polarity and epithelial cell functionality,
growth and nutrient signaling, energy homeostasis and
intestinal smooth muscle function. In order to reveal a
functional role for genes within these pathways in celiac
disease, small intestinal mRNA expression for 11 genes
were analyzed in a pediatric celiac disease case–control
cohort. Eight genes selected were previously found to be
differentially expressed in the small intestinal mucosa
between celiac disease patients and controls [7]. The
remaining three genes were included in a specific func-
tional cluster of cytoplasmic vesicle transport and
secretory granules and also expressed differently in the
small intestinal mucosa of celiac disease patients and
controls in a pilot performed in this study.
The purpose of this study was therefore to confirm the
differential gene expression in small intestinal biopsies
and peripheral blood using a larger collection of individ-
uals. Furthermore, we aimed to investigate if closely lo-
cated celiac disease associated SNPs from the sib-pair
GWAS inferred risk to disease by affecting biopsy and
peripheral blood mRNA expression levels of the eleven
differentially expressed genes. Several genes involved in
biological pathways of relevance for celiac disease patho-
genesis and previously not associated with celiac disease
at a transcriptional level were differentially expressed in
the small intestine and peripheral blood of our celiac
disease case–control cohort. Moreover, some of the
genes expression levels were associated with alleles of
previous celiac disease associated SNPs. This could indi-
cate a functional role for these genes in triggering and/
or upholding the disease.
Methods
Study subjects and diagnostic criteria
Biopsies from duodenum and peripheral blood samples
were consecutively collected from 402 children (167 with
celiac disease at median 7.1 years of age, 107 girls and 60
boys; 61 with potential celiac disease at median 8.8 years
of age, 42 girls and 19 boys; 174 controls at median
11.9 years of age, 97 girls and 77 boys) referred to upper
endoscopy at four Swedish pediatric gastroenterology
units located at Scania University hospital in Malmoe,
Södersjukhuset in Stockholm, Karolinska University hos-
pital in Stockholm and Queen Silvia Children’s hospital inGothenburg. All participants were informed about the aim
of the study and a parental written consent was obtained
for each child. The ethical committee at Gothenburg Uni-
versity approved the study.
In order to avoid variations in grading of the biopsies
by different pathologists in this multicenter study, biop-
sies from all the patients were in retrospect blindly clas-
sified by the same pathologist. Due to the commonly
observed atrophic patchiness of the duodenum in celiac
disease patients, classification was determined from a bi-
opsy in the same part of duodenum as the biopsy used
for gene expression analyses. For the purposes of this
study, celiac disease patients were defined as being posi-
tive for tissue transglutaminase (tTG) autoantibodies in
blood plasma as previously described [8] and a biopsy
showing characteristic villous atrophy of the distal part
of duodenum. Among the children with celiac disease, 6
had a Marsh score 2, 31 had a Marsh score 3a, 63 had a
Marsh score 3b and 67 a Marsh score 3c. Potential celiac
disease was defined as being tTG autoantibody positive
and having a normal biopsy. Children being tTG auto-
antibody negative with a normal biopsy were included as
disease controls.
Sample preparation
The intestinal biopsy was immediately after collection
put in the RNA stabilizing reagent RNAlater (Life Tech-
nologies, CA, US) and frozen in −80 °C until RNA ex-
traction was carried out using the miRNeasy Mini Kit
(Qiagen, Germany) or the Maxwell® 16 Total RNA Puri-
fication Kit (Promega). The RNA quality and quantity
was checked with a NanoDrop 2000 spectrophotometer
and a 2100 Bioanalyzer (Agilent Technologies).
Peripheral blood samples were also collected from
each patient, one in RNA stabilizing reagent (Tempus™),
one in lithium heparin and one in EDTA. DNA was ex-
tracted from EDTA stabilized whole blood using the
Maxwell® 16 LoDNA Purification Kit (Promega). RNA
was isolated from the Tempus™ tubes using the Tempus™
Spin RNA Isolation kit (Life Technologies, CA, US) or
the Maxwell® 16 Total RNA Purification Kit (Promega).
A DNase treatment with AbsoluteRNA was included in
the Tempus™ RNA extraction protocol. Complimentary
DNA (cDNA) was synthesized from total RNA using the
SuperScript VILO cDNA kit according to the manufac-
turers protocol (Life Technologies, CA, US).
Selection criteria for candidate genes
The 603 SNPs used to identify genes for the expression
analyses had previously been nominally associated with
celiac disease in our family GWAS [7]. The SNPs were
chosen based on three different inclusion criteria 1) p-
value < 3.0*10−4 in the transmission disequilibrium test
(TDT) 2) OR of <0.2 or >5 combined with p < 1.5*10−3 3)
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based GWAS [5]. Two different selection procedures were
used to choose the genes tested for mRNA expression in
small intestinal biopsies (Additional file 1: Figure S1: Se-
lection procedure for target genes). The first selection in-
cluded 8 genes previously found to be differentially
expressed in the small intestine between celiac disease pa-
tients and controls [7]. The second set included 54 genes
from the most significant functional annotation cluster
(Additional file 2: Table S1: cytoplasmic vesicle transport
and secretory granules) generated by DAVID (http://davi-
d.abcc.ncifcrf.gov/) as well as an additional 34 functionally
related genes.
Gene expression analyses and genotyping
In the following procedure, mRNA expression for all 96
selected target genes was measured in the small intestinal
mucosa using TaqMan technology. Eight genes (ADCY9:
Adenylate cyclase 9, APPL2: Adaptor protein, phosphotyro-
sine interaction, PH domain and leucine zipper containing
2, GLS: Glutaminase, INSR: Insulin receptor, KIF13A:
Kinesin family member 13A, PDK1: Pyruvate dehydrogen-
ase kinase isozyme 1, PPP1R12B transcript NM032103.2:
Myosin light chain phosphatase catalytic subunit 12B,
PRR5L: Proline rich 5 like) in the previous set of 35 target
genes were shown to be differentially expressed in the
small intestinal mucosa from a subset of 89 individuals
within our celiac disease case–control cohort in the paper
by Östensson et al. [7]. The second set of 88 target genes
and 8 reference genes were analyzed in this study using a
subset of 80 individuals and 384 well TaqMan low density
arrays (Life Technologies, CA, US). For each individual
and 96 gene set, 0.5 μg cDNA was loaded. Three genes
(HSPB1: Heat shock 27 kDa protein 1, NCALD: Neuro-
calcin δ, NTS: Neurotensin) from this pilot experiment
were differentially expressed between celiac disease pa-
tients and controls after correction for multiple testing
(Additional file 3: Table S2).
Gene expression for the 11 selected genes was further
analyzed in the small intestinal mucosa and in peripheral
blood from all 402 children in the celiac disease case–
control cohort. The TaqMan qPCR reaction was run in
duplicates and the samples were distributed randomly
on the plates with a final cDNA concentration of 1 ng/μl.
The raw data was analyzed using SDS version 2.4 and RQ
manager 1.2.1. Samples with a Ct replicate difference of
more than one cycle were excluded from analysis. Tran-
script quantification was determined using the ΔΔCt
method [9] where each target gene was normalized to an
arithmetic mean of the two reference genes TRAP1
(Hs00972326_m1) and ACTB (Hs00357333_g1). Evalu-
ation of reference gene stability in both tissues was per-
formed with the geNorm module in the qBasePLUS v2.1
(Biogazelle, Belgium). Genotyping of SNPs was performedwith KASP-technology (KBioscience/LGC Genomics) and
KASP-on-demand assays. All qPCR reactions and geno-
typing was run on a 7900HT Sequence Detection System
(Life Technologies, CA, US).
Statistical analyses
Gene expression levels in intestinal mucosa and periph-
eral blood were compared between groups using
deltaCt-values (i.e., log expression levels) as outcome in
linear model with age and sex as covariates. The allele
specific gene expression analysis was conducted in the
celiac disease group and control or potential celiac dis-
ease group separately using linear regression with allele
count as predictor and adjusted for age and sex. A logis-
tic regression model was used to associate allele count
with celiac disease outcome (potential celiac disease
merged with controls) and with subjects of non-
Caucasian origin excluded. Spearman rank test was
used to analyze the correlations in gene expression be-
tween tissues. A p-value <0.05 was considered signifi-
cant (Bonferroni-Holm procedure was used to correct
for multiple testing [10]). All statistical analyses were
conducted in R or SPSS version 21 for Windows (SPSS,
Chicago, IL, USA).
Results
In the pilot gene expression experiment of 88 target
genes in the small intestinal mucosa, only 44 genes
(50 %) were expressed by at least 50 % of the patients
(Additional file 4: Table S3) and three genes (NTS,
NCALD, HSPB1) showed a significant differential ex-
pression between cases and controls after correction for
multiple testing (Additional file 3: Table S2).
When including additional patients and controls we
could not detect any significant difference in gene ex-
pression between potential celiac disease patients and
controls in neither peripheral blood nor in the intestinal
biopsies (Fig. 1, blood data not shown). These two
groups were therefore combined and compared to bi-
opsy confirmed celiac disease patients. In an analysis in-
cluding only new cases and controls, all the 11 selected
target genes showed a significant differential expression
in the small intestinal epithelium (Table 1). Seven genes
were down-regulated in the biopsies of celiac disease pa-
tients, among them NTS down-regulated 3.6 fold and
the INSR, APPL2, ADCY9, GLS, HSPB1 and KIF13A 1.5-
2.2 fold in the patient group (p < 0.001). On the contrary,
four genes including the specific isoform C of PPP1R12B,
PRR5L, PDK1 and NCALD were up-regulated in the celiac
small intestinal mucosa (PPP1R12B fold change = 1.9;
PRR5L, PDK1 and NCALD fold change = 1.2-1.4). Biopsy
expression levels for all 11 genes significantly correlated to
the degree of lesion in the small intestine as well as to
plasma tTG autoantibody levels (data not shown). In
Fig. 1 Gene expression in small intestinal mucosa vs. celiac disease status. Fold change and p-value are presented for the celiac disease group
(n = 167) and the potential celiac disease group (n = 61) with the control group (n = 174) set as reference and adjusting for age and sex
Montén et al. BMC Medical Genetics  (2015) 16:44 Page 4 of 9peripheral blood, disease status affected the expression of
the APPL2 and NCALD genes (Table 1). The gene APPL2
was down-regulated and NCALD up-regulated in both
peripheral blood and the small intestine of celiac disease
patients. The expression levels correlated significantly be-
tween the two types of tissue (APPL2: r = 0.15, p = 0.01;
NCALD: r = 0.18, p = 0.002). The PPP1R12B isoform C
and NTS gene transcript was not expressed in peripheral
blood and the ADCY9, HSPB1 and PDK1 genes were ex-
cluded from analysis in peripheral blood due to problems
with transcript detection. No gene expression levels in
blood correlated with plasma tTG autoantibodies (data
not shown).
Four genes (GLS, INSR, KIF13A and NCALD) showed
allele specific gene expression in the small intestinal mu-
cosa that was dependent on the disease state of the pa-
tient (Fig. 2) (Table 2). In biopsies from celiac disease
patients, minor allele carriers of the INSR rs7254060
SNP showed decreased INSR gene expression levels
(INSR rs7254060; p = 0.003) and minor GLS rs6741418
carriers showed decreased GLS gene expression levels
(GLS rs6741418; p = 0.009). The NCALD gene expres-
sion in biopsies was decreased in celiac disease patientscarrying the minor allele of SNP rs652008 (p = 0.005).
We could not detect any allele specific gene expression
in peripheral blood (Table 2).
In the analyses comparing SNP alleles with celiac dis-
ease status (data not shown), the PRR5L intronic SNP
rs10501156 was associated with celiac disease. Minor al-
lele carriers of this SNP showed a decreased risk for ce-
liac disease compared to controls and potential celiac
disease patients (OR = 0.42; p = 0.007).
Discussion
In the present study we aimed to elucidate if non-coding
SNPs, previously associated with celiac disease in our
GWAS, could regulate nearby gene expression in the
small intestinal mucosa and in peripheral blood. Our
major finding was that four SNPs affected gene expres-
sion levels in the small intestinal mucosa and this was
dependent on celiac disease activity. All the eleven investi-
gated genes included those located close to the four sug-
gested eQTL SNPs, showed a differential biopsy expression
between children with celiac disease and those without the
disease. We could not detect any allele specific expression
in peripheral blood from the same individuals. However,
Table 1 a) Small intestinal biopsy and b) Peripheral blood gene expression vs. celiac disease status. Fold change and effect direction
is presented for the celiac disease group (n = 167) with the control and potential celiac disease group (n = 235) set as reference.
Individuals in the pilot data sets were excluded from the biopsy gene expression analysis. The analysis was adjusted for age and sex
in both tissues
a. Small intestinal biopsy
Gene symbol Gene name Fold (95 % CI) change pc
ADCY9 Adenylate cyclase 9 2.2 (1.8-2.7) DOWN 1.3E-13
APPL2 Adaptor protein, phosphotyrosine interaction,
PH domain and leucine zipper containing 2
1.9 (1.7-2.1) DOWN 1.9E-25
GLSa Glutaminase 2.0 (1.6-2.5) DOWN 1.1E-08
HSPB1 Heat shock 27 kDa protein 1 1.9 (1.5-2.3) DOWN 5.9E-08
INSR Insulin receptor 2.1 (1.8-2.5) DOWN 3.0E-18
KIF13A Kinesin family member 13A 1.5 (1.3-1.7) DOWN 3.6E-05
NCALD Neurocalcin delta 1.4 (1.2-1.6) UP 1.7E-04
NTS Neurotensin 3.6 (2.7-4.9) DOWN 5.5E-15
PDK1 Pyruvate dehydrogenase kinase, isozyme 1 1.3 (1.1-1.6) UP 7.5E-03
PPP1R12Ba Myosin light chain phosphatase catalytic subunit 12B 1.9 (1.6-2.2) UP 2.5E-12
PRR5L Proline rich 5 like 1.2 (1.1-1.4) UP 3.6E-03
b. Peripheral blood
Gene symbol Gene name Fold (95 % CI) change p (pc)
ADCY9 Adenylate cyclase 9 Low transcript quality Low transcript quality
APPL2 Adaptor protein, phosphotyrosine interaction,
PH domain and leucine zipper containing 2
1.3 (1.1-1.5) DOWN 0.003 (0.02)
GLSa Glutaminase 1.1 (0.8-1.4) DOWN 0.63
HSPB1 Heat shock 27 kDa protein 1 Low transcript quality Low transcript quality
INSR Insulin receptor 1.2 (1.0-1.4) DOWN 0.088
KIF13A Kinesin family member 13A 1.3 (1.0-1.8) UP 0.10
NCALD Neurocalcin delta 1.5 (1.1-2.0) UP 0.008 (0.04)
NTS Neurotensin Not expressed Not expressed
PDK1 Pyruvate dehydrogenase kinase, isozyme 1 Low transcript quality Low transcript quality
PPP1R12Ba Myosin light chain phosphatase catalytic subunit 12B Not expressed Not expressed
PRR5L Proline rich 5 like 1.3 (1.0-1.8) UP 0.081
aGene located in celiac disease genome-wide significant region
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between celiac disease patients and controls and the direc-
tion of the change was the same as in the small intestinal
mucosa and each gene correlated significantly between the
two tissues.
Two of our eleven selected genes (GLS and
PPP1R12B) map within celiac disease genome-wide sig-
nificant loci. Even though most of the selected SNPs that
are located close to the eleven genes are not genome-
wide significant, they could still be of interest when try-
ing to understand disease mechanisms. The genes that
were selected for this study are involved in epithelial cell
functionality, smooth muscle contractility and nutrient
signaling pathways, all of biological relevance for celiac
disease pathogenesis. Transcript levels for nearly all of
these genes have previously been analyzed in celiacdisease small intestinal mucosa [11]. However, none of
the genes have to our knowledge been previously associ-
ated with the disease at a transcriptional level or with
celiac disease risk SNPs. Altered expression in small in-
testinal celiac disease mucosa have previously been ob-
served for other genes involved in similar pathways like
cell proliferation and differentiation, apoptosis, transport
and metabolism [11, 12]. In one such study, a majority
of the genes involved in cell proliferation and differenti-
ation pathways showed a decreased gene expression in
biopsy confirmed celiac disease patients [11]. Most of
the genes in our expression analysis were likewise down-
regulated in the small intestine of celiac disease patients
compared with controls. The NTS transcript was down-
regulated 3.6 fold in celiac disease mucosa but not de-
tected in peripheral blood. The NTS encoded
Fig. 2 Allele specific gene expression in the small intestinal mucosa. The analysis was performed in celiac cases and controls separately using
linear regression adjusting for age and sex to correlate expression levels to minor allele count
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system but also act as a hormone in the gastrointestinal
tract where its main function is to control smooth
muscle contractions stimulated by intake of fat [13]. The
role of NTS as a protector of intestinal atrophy by redu-
cing the rate of apoptosis in intestinal crypts was re-
cently suggested [14]. The NTS peptide has also been
shown to stimulate epithelial restitution following a
chronic intestinal inflammation in mouse colon through
up-regulation of a COX-2 dependent pathway [15]. Re-
newal of epithelial cells in the gut is a continuous
process dependent on a proper balance between prolifer-
ation and apoptosis. Increased apoptosis and crypt cell
proliferation has previously been observed in active ce-
liac disease [16]. Altered expression of genes in the con-
trol of this balance could lead to crypt hyperplasia and
eventually to villous atrophy.
We observed a tissue specific expression for the
PPP1R12B isoform C, which was up-regulated in celiac
disease intestinal mucosa albeit not expressed in periph-
eral blood. The PPP1R12B protein is a phosphatase that
in similarity to NTS control muscle contractility and
when activated causes muscle relaxation [17]. Thespecific PPP1R12B isoform encodes a 208 amino acid
long C-terminal part of the protein (called small subunit
M20) that interacts with the interleukin-16 (IL-16) pre-
cursor protein pro-IL-16 [18, 19]. Mature IL-16 function
as a chemo attractant factor for CD4+ T-cells and also
regulate HLA class II expression and release of other
pro-inflammatory cytokines [20]. Although its effect of
interaction with PPP1R12B is currently unknown, it in-
dicates a connection between changes in cytoskeleton
rearrangements and the immune response predisposing
to the chronic inflammation in celiac disease.
In the current study, we focused on SNPs in cis pos-
ition of target genes since previously other celiac disease
associated SNPs were shown to affect nearby gene ex-
pression levels [5]. SNPs in a cis position could alter
gene expression levels, timing and localization by alter-
ing binding sites for transcription regulatory proteins
[21]. Several of the SNPs affecting gene expression levels
in our study are known to act as binding sites for tran-
scription factors (rs6741418-EP300, rs7254060-NFKB1,
rs652008-GATA5-6) and are therefore likely to have a
functional effect [22]. A nominally significant effect of
our analyzed SNP rs6741418 on GLS gene expression
Table 2 a) Small intestinal biopsy or b) Peripheral blood gene expression levels vs SNP. The analysis was stratified according to
disease status and performed in the celiac disease group (n = 167) and control or potential celiac disease group (n = 235) separately
Controls & PCD Celiac disease
a. Small intestinal biopsy
Gene symbol SNP ID Allelesa Fold change p Fold change p (pc)
ADCY9b rs882820 G:A 1.04 UP 0.67 1.21 DOWN 0.08
APPL2 rs10861406 G:A 1.01 DOWN 0.88 1.01 DOWN 0.79
GLSb,c rs6741418 C:T 1.04 UP 0.71 1.47 DOWN 0.009
HSPB1 rs1019096 G:A 1.03 DOWN 0.77 1.05 DOWN 0.66
INSRb rs7254060 G:A 1.05 DOWN 0.61 1.51 DOWN 0.003 (0.03)
KIF13A rs9396802 C:T 1.11 DOWN 0.04 1.09 DOWN 0.22
NCALDb rs652008 C:T 1.00 DOWN 0.97 1.24 DOWN 0.005 (0.05)
NTSb rs11104365 C:T 1.02 UP 0.85 1.17 DOWN 0.33
PDK1b rs4972810 G:A 1.03 DOWN 0.85 1.09 DOWN 0.71
PPP1R12Bc rs12734338 T:C 1.02 UP 0.95 1.04 UP 0.42
PRR5L rs10501156 C:A 1.07 DOWN 0.29 1.62 DOWN 0.92
b. Peripheral blood
Gene symbol SNP ID Allelesa Fold change p Fold change p
ADCY9b rs882820 G:A Low transcript quality Low transcript quality
APPL2 rs10861406 G:A 1.02 UP 0.85 1.00 UP 0.97
GLSb,c rs6741418 C:T 1.23 DOWN 0.18 1.31 DOWN 0.15
HSPB1 rs1019096 G:A Low transcript quality Low transcript quality
INSRb rs7254060 G:A 1.10 UP 0.45 1.18 DOWN 0.43
KIF13A rs9396802 C:T 1.07 DOWN 0.59 1.01 DOWN 0.97
NCALDb rs652008 C:T 1.15 UP 0.29 1.03 DOWN 0.85
NTSb rs11104365 C:T Not expressed Not expressed
PDK1b rs4972810 G:A Low transcript quality Low transcript quality
PPP1R12Bc rs12734338 T:C Not expressed Not expressed
PRR5L rs10501156 C:A 1.22 DOWN 0.46 1.15 DOWN 0.64
The p-values represent the association between gene expression and minor allele count using a linear regression model corrected for age and sex
Significant associations are shown in bold type
aMinor allele in bold type
bGene with an eQTL effect in peripheral blood according to the Blood eQTL browser
cGene located in celiac disease genome-wide significant region
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celiac disease patients. This SNP is located in one of the
strongest GWAS celiac disease risk loci about 22 kb up-
stream of the GLS gene. A previous GLS promoter ana-
lysis identified several binding sites for the STAT1
transcription factor and revealed that cytokine (IFN-α)
mediated activation of the GLS promoter requires
STAT1 phosphorylation [23]. In our patients, GLS gene
expression was significantly decreased 2-fold compared
to controls and a decreased GLS activity has previously
been observed in the intestine of untreated celiac disease
patients [24]. The main function of GLS is to convert
glutamine to glutamate and ammonia, an important
process to maintain energy balance in the gut.
Other studies have investigated and some also found
allele specific gene expression in the small intestinalmucosa in celiac disease although performed in very
small sample sizes [25, 26]. Important factors to consider
when studying small changes in gene expression caused
by non-coding SNPs in complex diseases are the use of
relevant tissue or cell type under the right conditions
and use of sufficiently large datasets. Several eQTL data-
bases include more easily accessible peripheral blood
samples or specific isolated blood cell populations, the
largest being the blood eQTL database [27] and a mono-
cyte dataset of 1490 unrelated individuals [28]. Compar-
ing our data with these databases we found that six of
our analyzed genes (GLS, NCALD, INSR, ADCY9, NTS,
PDK1) previously have shown significant eQTL effect in
peripheral blood. In our study, three of these six genes
(GLS, NCALD, INSR) showed a significant eQTL effect
and were also differentially expressed in the small
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librium (LD) with two nominally significant NCALD
eQTL SNPs in the database. The remaining genes in the
database were in eQTL with other SNPs than our se-
lected one. Two SNPs that failed to show an allele spe-
cific effect in our study has been shown to affect the
expression of another closely located gene (rs10501156-
TRAF6 [29], rs1019096-ZP3 [28, 30]) and two of our
suggested eQTL SNPs (rs6741418/GLS and rs7254060/
INSR) are in LD with another SNP that is associated
with a specific phenotype (rs6741418/rs10497709: fast-
ing triglyceride levels [31], rs6741418/rs3024896: fasting
insulin levels [32], rs7254060/rs2115386: diabetic retin-
opathy [33]). Other SNPs have been shown to affect ex-
pression levels for some of our target genes in brain
tissue (PRR5L), liver (INSR, ADCY9) and lymphoblas-
toids (APPL2) according to the NCBI eQTL browser.
A major advantage with our study is the large collection
of biopsies from over 400 individuals which increases our
power to detect differences in gene expression especially
against variants with lower allele frequency. Another ad-
vantage is that the diagnosis of our patients is determined
from a biopsy in the same part of duodenum as the biopsy
used for gene expression analyses. This is important in
order to avoid biased gene expression results due to the
commonly observed patchy inflammation in the celiac dis-
ease small intestinal mucosa. A possible problem that
could give a bias to the observed differential expression in
our study is the heterogeneous cell population in the biop-
sies. However, a majority of the selected genes in this study
are not known to be preferentially expressed by specific
cell types that could have been lost due to villous atrophy.Conclusion
We have shown that some of our celiac disease associ-
ated SNPs from our published family GWAS affect tran-
scription in the small intestinal epithelium of genes not
previously implicated in the disease. The differential ex-
pression of NTS and PPP1R12B indicate a potential role
for smooth muscle contractility and cell proliferation,
whereas other genes like GLS, NCALD and INSR sug-
gests involvement of nutrient signaling and energy
homeostasis in celiac disease pathogenesis. Individuals
being genetically susceptible for the effect of gluten on
these pathways might be more prone to trigger the im-
mune system and develop celiac disease. The proposed
functional role of the genes and variants in celiac disease
should be further addressed at post-translational level
and in specific disease cell populations.Additional files
Additional file 1: Figure S1. Selection procedure for candidate genes.
Two different procedures used for selection of candidate genes for pilot
expression analysis in small intestinal biopsies. 1Ostensson M et al., PloS
one 2013, 8 (8).
Additional file 2: Table S1. The top three functional annotation cluster
generated in DAVID. Genes from cluster 1 were chosen for gene
expression analyses in small intestinal biopsies from our celiac disease
case control cohort.
Additional file 3: Table S2. Expressed genes in pilot analysis of 88
genes in the small intestinal biopsies from 80 children. Genes from the
most significant DAVID annotation cluster and associated pathways were
selected. Transcript levels were compared to celiac disease status (42 celiac
disease patients, 38 disease controls) using two-sample t-test and significant
associations (p < 0.05) after Bonferroni correction are shown in bold.
Additional file 4: Table S3. Unexpressed genes in pilot analysis of 88
genes in the small intestinal biopsies from 80 children. Modestly expressed
genes (>50 % of the children with transcript levels Ct > 40) were excluded
from further analysis.
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